Join to View Full Profile
10903 New Hampshire AveSilver Spring, MD 20903
Phone+1 408-338-9955
Dr. Wu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Office of Vaccines Research and Review
Education & Training
National Institutes of Health Clinical CenterResidency, Allergy and Immunology, 2019 - 2022
National Capital ConsortiumResidency, Internal Medicine, 2016 - 2019
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2016
Certifications & Licensure
DC State Medical License 2019 - 2026
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Outstanding Service Medal United States Public Health Service, 2023
- NIAID Merit Award National Institute of Allergy and Infectious Diseases, 2022
- Presidential Unit Citation Medal President of the United States of America, 2015, 2021
- Join now to see all
Clinical Trials
- Trial to Evaluate L9LS in Healthy Adults Start of enrollment: 2021 Sep 13
- Trial to Evaluate CIS43LS in Healthy Adults Start of enrollment: 2020 Jan 07
- Anti-malaria MAb in Malian Children Start of enrollment: 2022 Mar 18
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsPhase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.Joseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, LaSonji A Holman, Cynthia S Hendel
NPJ Vaccines. 2024-09-17 - 7 citationsLow-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan
The Lancet. Infectious Diseases. 2023-05-01 - 46 citationsLow-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.Richard L Wu, Azza H Idris, Nina M Berkowitz, Myra Happe, Martin R Gaudinski
The New England Journal of Medicine. 2022-08-04
Press Mentions
Monoclonal antibody treatment for malaria shows encouraging resultsAugust 4th, 2022
Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial ShowsAugust 4th, 2022
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
